GILD

Gilead Sciences Stock Price

59.85
-0.11 (-0.18%)
Upgrade to Real-Time
Afterhours (Closed)
59.85
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Gilead Sciences Inc GILD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.11 -0.18% 59.85 19:59:40
Close Price Low Price High Price Open Price Previous Close
60.01 59.44 60.208 59.81 59.96
Bid Price Ask Price Spread News
59.75 59.95 0.20 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
62,789 7,699,866 $ 59.88 $ 461,038,917 9,666,130 59.4001 - 89.00
Last Trade Time Type Quantity Stock Price Currency
19:59:40 67 $ 59.77 USD

Gilead Sciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 75.04B 1.25B 1.25B $ 22.45B $ 4.08B 4.21 18.39
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ 2.52 4.21% - -

more financials information »

Gilead Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GILD Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week60.5963.6459.400160.5614,489,020-0.74-1.22%
1 Month62.9364.9959.400162.089,925,203-3.08-4.89%
3 Months72.0972.189659.400164.749,293,380-12.24-16.98%
6 Months79.9087.6659.400171.9810,518,690-20.05-25.09%
1 Year63.6389.0059.400172.0012,859,291-3.78-5.94%
3 Years75.0189.5459.400171.368,914,795-15.16-20.21%
5 Years109.39111.1159.400175.198,988,899-49.54-45.29%

Gilead Sciences Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.